Darius Kharabi - Nov 15, 2021 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Stock symbol
KALA
Transactions as of
Nov 15, 2021
Transactions value $
$0
Form type
4
Date filed
11/17/2021, 07:02 PM
Next filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Award +296K 296K Nov 15, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALA Stock Option (right to buy) Award $0 +100K $0.00 100K Nov 15, 2021 Common Stock 100K $2.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). On November 15, 2021, in connection with the Acquisition, the reporting person acquired the right to receive an aggregate of 295,657 shares of the Issuer's common stock (the "Shares") in exchange for 323,415 shares of Combangio's common stock and for an option to purchase 8,754,216 shares of Combangio's common stock. On November 12, 2021, the last trading day prior to the closing of the Acquisition, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.07 per share. Of the 295,657 Shares, (i) 230,991 Shares are to be issued by the Issuer to the reporting person on January 3, 2022 and (ii) 64,666 Shares are being held back by the Issuer and will be issuable fifteen months after the closing of the Acquisition and will serve as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders.
F2 This option was granted on November 15, 2021 and vests over four years beginning on the vesting commencement date of November 15, 2021, with 25% of the shares underlying the option vesting on November 15, 2022, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.